Across
- 7. Treats chronic angina by inhibiting late phase of inward sodium channels, rapid delayed rectifier potassium current, and fatty acid oxidation
- 9. Inhibits the production of prostaglandins to reduce inflammation and fever, produces analgesia. Reduces platelet aggregation.
- 10. K1 Dietary supplement that helps synthesize prothrombin and clotting factors II, VII, IX, and X
- 11. Directly inhibits thrombin; stops the conversion of fibrinogen to fibrin and prevents clotting factors from activating
- 13. Hydrochloride Treats arrhythmias by slowing the travel of sodium through fast sodium channels, reducing the excitability of the heart, decreasing myocardial contraction, and slowing myocardial electrical conduction
- 17. Competitively inhibits ACE to prevent conversion of angiotensin I to angiotensin II; reduces vasoconstriction and aldosterone secretion, leading to sodium excretion and potassium retention
- 18. Blocks stimulation of beta1and beta2 adrenergic receptor sites, decreasing heart rate, contractility, oxygen demand, and blood pressure.
- 20. Factor X inhibitor that prevents DVT, with or without PE
- 21. preventing platelet adhesion.
- 23. Prevents strokes related to atrial fibrillation, DVT, PE
- 24. Administered subcutaneously or intravenously (IV), usually every 12 hours to treat and manage ischemic strokes, PEs, and DVTs
- 28. Ethyl treats severe hypertriglyceridemia, cardiovascular risk reduction post MI
- 30. Treats acute MI, pulmonary embolism, acute ischemic stroke, occluded intravenous catheters
- 31. Acid Binds plasminogen and plasmin to treat heavy menstrual bleeding and to prevent bleeding in cardiac surgeries with cardiopulmonary bypass, major orthopedic surgeries, hemorrhagic shock and trauma
- 32. treats angina pectoris, hypertensive emergencies, acute myocardial infarction, heart failure
Down
- 1. treats hypercholesterolemia, hypertriglyceridemia, and dysbetalipoproteinemia
- 2. Inhibits sodium-potassium adenosine triphosphatase (ATPase) pump to treat atrial flutter, atrial fibrillation, and HF
- 3. Selectively block the binding of angiotensin II to its receptors in the blood vessels, leading to vasodilation, treating hypertension
- 4. Treats unstable angina; secondary prevention measure after MI, stroke, and peripheral arterial disease
- 5. Reinstates sinus rhythm by slowing the speed of impulses traveling through the AV node
- 6. Reduce LDL levels for clients who have known ASCVD or a high risk for ASCVD, stroke, and unstable angina;
- 8. Factor Replaces factor VIII
- 12. Reduces the risk of clot formation, specifically DVTs, that result from conditions such as atrial fibrillation. Also used to treat DVT and PE.
- 14. treats supraventricular and ventricular arrhythmias
- 15. Treats symptomatic bradycardia, decreases oral and respiratory secretion preoperatively, antidotefor cholinergic agonists and poisoning
- 16. Selectively inhibits thrombin-induced platelet activation and reduces platelet-driven
- 19. During depolarization, prevents calcium ions from going into the slow calcium channels in the myocardium or vascular smooth muscle, converting supraventricular tachyarrhythmias to sinus rhythm
- 20. Manages acute coronary syndrome; indicated for clients receiving percutaneous coronary intervention
- 22. Promotes hemostasis by mimicking activated factor VIII. Prophylactic treatment of hemophilia A
- 25. Blocks beta1 adrenergic receptors in the heart, reducing heart rate, myocardial contractility, and cardiac output.
- 26. Interrupts the vitamin K cycle and reduces the creation of active clotting factors, preventing venous or arterial thrombosis and embolism
- 27. treats von Willebrand disease, hemophilia A, decrease nocturnal urination, diabetes insipidus
- 29. Attaches to glycoprotein IIb/IIIa receptors on platelets, which prevents them from clumping together and forming clots